NEW YORK (360Dx) – Amydis Diagnostics said that the National Institute on Aging had awarded it a Phase 2 SBIR grant of $1.8 million to fund R&D into an ophthalmic diagnostic probe for Alzheimer's disease.

The ability to identify amyloid-beta deposits helps in identifying patients at risk for Alzheimer's disease and enables enrollment of patients in clinical trials investigating disease modifying treatments, and may ultimately guide therapeutic intervention at an early stage, the firm said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.